

Resource Summary Report

Generated by SPARC SAWG on Aug 10, 2026

Phospho-c-Raf (Ser259) Antibody

RRID:AB_330759

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 9421, RRID:AB_330759

Antibody Information

URL: http://antibodyregistry.org/AB_330759

Proper Citation: Cell Signaling Technology Cat# 9421, RRID:AB_330759

Target Antigen: Phospho-c-Raf (Ser259)

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W, IP. Consolidation on 10/2018: AB_10078658, AB_10836482, AB_330759.

Antibody Name: Phospho-c-Raf (Ser259) Antibody

Description: This polyclonal targets Phospho-c-Raf (Ser259)

Target Organism: rat, xenopusamphibian, h, m, mouse, r, x, human

Antibody ID: AB_330759

Vendor: Cell Signaling Technology

Catalog Number: 9421

Record Creation Time: 20250820T003627+0000

Record Last Update: 20250820T084326+0000

Ratings and Alerts

No rating or validation information has been found for Phospho-c-Raf (Ser259) Antibody.

No alerts have been found for Phospho-c-Raf (Ser259) Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 12 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Kondo Y, et al. (2026) Mechanism of MEK1 phosphorylation by the N-terminal acidic motif-mediated asymmetric BRAF dimer. *Molecular cell*.

Bajikar SS, et al. (2024) Modeling antisense oligonucleotide therapy in MECP2 duplication syndrome human iPSC-derived neurons reveals gene expression programs responsive to MeCP2 levels. *Human molecular genetics*.

Wang Y, et al. (2023) Repositioning Lomitapide to block ZDHHC5-dependant palmitoylation on SSTR5 leads to anti-proliferation effect in preclinical pancreatic cancer models. *Cell death discovery*, 9(1), 60.

Qian F, et al. (2023) Activation of GPR44 decreases severity of myeloid leukemia via specific targeting of leukemia initiating stem cells. *Cell reports*, 42(7), 112794.

Zhang K, et al. (2023) Targeting GPR65 alleviates hepatic inflammation and fibrosis by suppressing the JNK and NF- κ B pathways. *Military Medical Research*, 10(1), 56.

Wong S, et al. (2023) RAF1 deficiency causes a lethal syndrome that underscores RTK signaling during embryogenesis. *EMBO molecular medicine*, 15(5), e17078.

Xia Y, et al. (2023) Repositioning of Montelukast to inhibit proliferation of mutated KRAS pancreatic cancer through a novel mechanism that interfere the binding between KRAS and GTP/GDP. *European journal of pharmacology*, 961, 176157.

Gao X, et al. (2022) Lyso-PAF, a biologically inactive phospholipid, contributes to RAF1 activation. *Molecular cell*, 82(11), 1992.

Joshi S, et al. (2021) Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer. *Communications biology*, 4(1), 1333.

Liao S, et al. (2019) Tanshinol borneol ester, a novel synthetic small molecule angiogenesis stimulator inspired by botanical formulations for angina pectoris. *British journal of pharmacology*, 176(17), 3143.

Lian X, et al. (2019) The combination of metformin and 2-deoxyglucose significantly inhibits cyst formation in miniature pigs with polycystic kidney disease. *British journal of pharmacology*, 176(5), 711.

Sulahian R, et al. (2019) Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers. *Cell reports*, 29(1), 118.